Current Editions
Vectorized antibodies are taking gene therapy beyond rare disease
ASGCT presentations showcase cancers, infectious diseases and chronic inflammatory conditions as potential applications of vectorized antibodies
Product Development
Data Byte
FDA label expansions: Full approval for Tivdak in April
Plus: Tissue agnostic accelerated approval for Enhertu
Discovery & Translation
Brain-penetrant AAV capsid progress at ASGCT
Companies and academics showcase two approaches to make AAV capsids with enhanced brain targeting and suppressed liver targeting
Finance
Hengrui metabolic programs spun out into start-up with $400M
Bain, RTW, Atlas and Lyra back freshly created company with implied $570M valuation
Public Equity Report: Erasca reboots, Telix plans NASDAQ listing
Plus: OnKure goes public via reverse merger, Monte Rosa and Allogene each raise $100M+, and Incyte’s $2B buyback
Management Tracks
Hutchmed names new chairman as Simon To retires
Plus: Immunome promotes Max Rosett to CFO, and Mark de Jong becomes CTO at Full-Life
BioCentury ISSN 1097-7201